Aelis Farma Announces 2025 Financial Calendar: A Glimpse into the Future of Brain and Peripheral Disease Treatments

Aelis Farma SA, a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, has announced its indicative financial calendar for the financial year 2025. This announcement provides investors and stakeholders with key dates for financial reporting and shareholder engagement, offering valuable insights into the company's strategic objectives and milestones in drug development.

The company's financial calendar for 2025 includes the following events:

1. 2024 Annual Results (April 1, 2025): This event will provide an overview of Aelis Farma's financial performance for the full year 2024, allowing investors and stakeholders to assess the company's progress towards its strategic objectives. The results will also offer insights into the company's research and development efforts, including the progress of its drug candidates, AEF0117 and AEF0217.
2. Annual General Meeting (May 27, 2025): The Annual General Meeting is an opportunity for shareholders to engage with the company's management, discuss the company's performance, and vote on key decisions. This event is essential for maintaining transparency and accountability, which are crucial for building trust with investors and other stakeholders.
3. 2025 Half-Year Results (September 22, 2025): The half-year results will provide an update on Aelis Farma's financial performance and progress in its drug development programs. This event is particularly important for tracking the company's progress towards its strategic milestones, such as the completion of clinical trials for AEF0117 and AEF0217.

Aelis Farma's financial calendar for 2025 aligns with its strategic objectives and milestones in drug development, ensuring that investors and stakeholders have access to timely and relevant information. By closely monitoring these events and the company's financial performance, investors can make informed decisions about their investments in Aelis Farma.

Aelis Farma's financial calendar for 2025 is an essential tool for investors and stakeholders to stay informed about the company's progress and make data-driven decisions. By attending these key events and staying up-to-date with the company's financial performance, investors can better understand the value and potential of Aelis Farma's drug candidates and the company's overall strategy in the brain and peripheral disease treatment landscape.